Media-News

Be the most trusted biotech company

2023-02-10

First Patient in the US Dosed in a Global Multicentre Phase 3 Clinical Study of Henlius Bevacizumab for Treatment of Ophthalmic Diseases
2023-02-03

Nature Medicine Published the Results of ASTRUM-007: HANSIZHUANG Combined with Chemotherapy for the First-line Treatment of Esophageal Squamous Cell Carcinoma
2023-02-02

Henlius completed the phase 1b/2 clinical trial of HLX07 for the treatment of advanced solid tumours
2023-02-01

First Subject Dosed for Phase 1 Clinical Trial of Henlius’ Daratumumab Biosimilar HLX15
2023-01-17

Henlius’ Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Approved for the Treatment of ES-SCLC
2023-01-05

First Patient Dosed for MRCT Phase 3 Study on First-Line LS-SCLC of Henlius Anti-PD-1 mAb Serplulimab in the US
2022-12-27

Henlius and Fosun Pharma Entered into an Exclusive License Agreement for HANSIZHUANG in the US
2022-12-15

First Patient Dosed in a Phase 1 Clinical Study of Henlius Novel Anti-GARP and Anti-PD-1 Dual mAb Therapy in Australia
2022-12-15

HANSIZHUANG Granted Orphan Drug Designation in the European Union for Small Cell Lung Cancer